Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it.
The team also discusses what lessons can be learned from the regulatory roller-coaster ride of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point in treating depression.

View full story: https://www.biocentury.com/article/660376

#BiotechMA #FDA #Psychedelics #Depression #OncolyticVirus

00:00 - Introduction
00:51 - AZ-BMS Rumors
08:07 - Replimune
20:46 - Psychedelics

To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

Reach us by sending a text